January 30, 2023
6 min watch
Artificial intelligence tool may help predict lung cancer risk regardless of smoking history
Source/Disclosures
Published by:
Disclosures:
Fintelmann reports consulting or advisory roles with Jounce Therapeutics and Pfizer, research funding to his institution from BTG Specialty Pharmaceuticals; royalties from writing a book with Elsevier; and a patent related to body composition analysis on CT scans. Sequist reports consulting/advisory roles with AstraZeneca, Genentech/Roche, Janssen, Pfizer and Takeda, as well as research funding to her institution from AstraZeneca, Boehringer Ingelheim, Delfi Diagnostics and Novartis. Please see the study for all other authors’ relevant financial disclosures.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
An artificial intelligence tool predicted a person’s lung cancer risk after analyzing a single low-dose CT scan, according to study results.
The tool, known as Sybil, accurately predicted risk for individuals with or without smoking history.
Researchers validated Sybil using three independent data sets, and the findings suggest the tool could help personalize lung cancer screening for those at greatest risk.
Healio spoke with researchers Lecia Sequist, MD, MPH, director of Center for Innovation in Early Cancer Detection and lung cancer medical oncologist at Mass General Cancer Center, and Florian Fintelmann, MD, of the department of radiology in the division of thoracic imaging and intervention at Massachusetts General Hospital, about the findings and their potential implications.
